Figure 3 provides the pathological outcomes of these two groups. According to the grading system for pancreatic cancer in AJCC 8th edition, most patients in this study hadstage I or II diseases, including all patients in the PD groupand 26 patients (92.86%) in the PD +IPHP group. The PD +IPHP group included stage IA in 2 patients (7.14%)